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Summary
Background: Vinorelbine, is an active drug in the treatment of
metastatic breast cancer and has a favorable toxicity profile. Its
combination with other effective and well-tolerated cytotoxics
may thus be beneficial. We investigated the therapeutic effect of
a combination of vinorelbine plus 5-fluorouracil and folinic
acid as first-line treatment in patients with metastatic breast
cancer.
Patients and methods: Forty-five patients with advanced or
metastatic breast cancer were enrolled in this phase I—II study
and treated with 5-fluorouracil (350 mg/m2 i.v. on day 1 to 3),
folinic acid (100 mg/m2 i.v. on day 1 to 3) and vinorelbine given
on days 1 and 3 at the dose of 25 mg/m2 (dose level 1), or 30
mg/m2 (dose level 2). Therapy was given on an outpatient basis
every three weeks.
Results: Phase I: Dose limiting toxicity (DLT) occurred at
the second dose level of vinorelbine (30 mg/m2), with two out
of three patients developing severe constipation ('ileus-like
syndrome' grade 4), and fever (grade 2). Consequently, the
dose evaluated in the phase II study was 25 mg/m2. Phase II:
Objective responses were observed in 24 of 39 evaluable
patients (95% confidence interval (95% CI), 47% to 77%).
There were seven complete responses (18%), 17 partial re-
sponses (44%), and for nine patients (23%) disease was stable.
Only six patients (15%) experienced disease progression. The
median response duration was 10 months (range 6 to 24+) and
the median time to progression was eight months (range 2 to
24+). Granulocytopenia was the most frequently observed side
effect, with a grade 4 nadir being observed in 30 patients
(77%), with four hospital admissions due to febrile neutro-
penia. Nausea, vomiting, and anorexia were mild to moderate
and reported by less than half of the patients. Alopecia was
moderate and occurred in about one-third of the patients. The
other side effects were mild and easily manageable.
Conclusions: This effective combination chemotherapy of
vinorelbine, 5-fluorouracil and folinic acid is comparable to
other first-line regimens in terms of efficacy, and is subjectively
well tolerated, thus deserving a test in randomized trials in the
advanced and adjuvant settings.
Key words: breast cancer, chemotherapy, fluorouracil, folates,
vinorelbine
Introduction
Polychemotherapy regimens containing anthracyclines
or taxanes, often used as first- or second-line systemic
treatments for patients with advanced breast cancer,
yield response rates of 50% to 70% with a median
duration of 8-16 months. Patients selected to be treated
with these regimens are reported to have a median over-
all survival of less than two years [1].
In most patients disease progression, after first-line
chemotherapy, typically requires a second-line chemo-
therapy. Anthracyclines are often given to achieve pal-
liation, but their increased employment in the adjuvant
setting represents a hindrance, thus demand the testing
of new effective regimens with a favorable therapeutic
index. Patients who relapse or have progressive disease
during or immediately after anthracycline treatment
have a poor prognosis, and a less than 15% chance of
achieving an objective response when treated with cyto-
toxic agents such as cisplatin, mitomycin-C or mitoxan-
trone [1]. Higher response rates of 20% to 30% have
been reported with taxanes [2], the use of which is,
however, associated with some unpleasent cumulative
side effects, especially in responders who require longer
treatment duration. The developement of effective and
well tolerated second-line regimens in this setting is
therefore a genuine clinical challenge.
Vinorelbine is a semisynthetic vinca alkaloid that has
cytocidal effect on a wide range of tumor cell lines [3-6].
It is a mitotic inhibitor that has a higher therapeutic
index and less neurotoxicity than other vinca alkaloids
related to the lower degree of damage of axonal micro-
tubules [7]. The dose limiting toxicity of vinorelbine is
granulocytopenia [8].
Given as single agent the drug yields response rates of
40% to 60% in previously untreated patients [9-13], and
of about 30% when used as a second- or third-line
therapy [14-17].
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A randomized study comparing vinorelbine with
melphalan in patients with anthracycline-refractory
metastatic breast cancer demonstrated the superiority
of vinorelbine in terms of response rates, time to disease
progression and median survival [18].
The impressive effectiveness observed with vinorel-
bine as single agent and its favorable toxicity profile led
to its testing in combination with other cytotoxics in
metastatic breast cancer setting. Such regimens included
doxorubicin, with response rates similar to some most
effective standard combinations [19], mitoxantrone [20,
21] and 5-fluorouracil [22].
We therefore started a phase I study in metastatic
breast cancer using vinorelbine together with 5-fluoro-
uracil and folinic acid, a combination based upon the
efficacy of both drugs in breast cancer, the low burden of
subjective side-effects associated with their use, and
their different toxicity profiles, 5-fluorouracil being
moderately myelotoxic.
The aims of this study were: a) to evaluate the
feasibility of such regimen and b) to establish the Maxi-
mum Tolerated Dose (MTD) of vinorelbine when ad-
ministered in a three-day schedule with 5-fluorouracil
and high-dose folinic acid.
Since we obtained good results in the first six patients
[three at first dose level of vinorelbine (25 mg/m2)] and
three at second dose level (30 mg/m2), we started a
phase II study in order to evaluate the activity of this
regimen as first-line treatment for patients with meta-
static breast cancer. We decided to administer high
doses of folinic acid in an attempt to maximize the effect
of the three-day schedule of low-dose 5-fluorouracil
[23, 24].
The combined data from these two investigations are
the subject of this report.
Patients and methods
Eligibility criteria
Patients with histologically proven, measurable or evaluable progres-
sive metastatic breast cancer, who had not received chemotherapy for
metastatic disease, were eligible for this study. The other eligibility
criteria were an age of more than 18 years; an ECOG performance
status of 0-2; an expected survival >3 months; reasonable bone
marrow function (absolute granulocyte count >4000/mm3, platelet
count > 100.000 /mm3, and hemoglobin level >11 g/dl); adequate
hepatic and renal function, including AST, ALT, bilirubin, alkaline
phosphatase and serum creatinine values < 1.25 times the upper limit
of normal; no severe uncontrolled co-morbidities and no second
malignancies. Informed consent was obtained before entry.
Clinical monitoring was performed once weekly with a complete
blood count.
Toxicity was evaluated according to NCIC-CTG criteria by clinical
and laboratory evaluations at day 21 of each cycle.
Antitumor activity was evaluated every two courses (i.e., six weeks)
on all measurable lesions and all of the patients were scheduled for at
least two cycles in order to be eligible for assessment of tumor
response. In patients with tumor responses or stable disease, the treat-
ment was continued to a maximum of eight cycles.
Tumor response was classified according to WHO criteria and
documented by two investigations at least six week apart.
Complete response (CR) was defined as the disappearance of all
clinical evidence of active tumor, with complete reossification of bone
lesions and the absence of any disease-related symptoms for a minimum
four weeks. Partial response (PR) was defined as a > 50% reduction in
the sum of the products of the perpendicular diameters of all meas-
urable lesions, without the appearance of any new lesions for at least
four weeks. In the case of multiple metastatic sites of disease, the
largest masses (up to five) were considered as the index lesions.
Minor response (MR) was defined as a decrease in tumor size of
less than 50% but more than 25%, for at least four weeks. Stable
disease (SD) was defined as a less than 25% decrease or a less than
25% increase in tumor size for at least four weeks. Progressive disease
(PD) was denned as the unequivocal appearance of any new lesion or
an increase of > 25% in the sum of the perpendicular diameters of any
measured lesion or in the estimated size of an unmeasurable lesion.
MR, SD, and PD were considered to be treatment failures.
The Kaplan-Meier method was used to analyse the time to pro-
gression (1 IF) and overall survival (OS) [25]. The confidence intervals
for the response rates were calculated by means using the method
described by Simon [26]. The sequential two-step statistical test of
Gehan was used to define the number of patients required to detect
activity of the treatment [30].
Treatment plan
Phase I
The treatment consisted of a fixed dose of 100 mg/m2 folinic acid (levo
isomer) administered by injection into a running intravenous (i.v.)
infusion of dextrose 5% or normal saline over a period of 10 minutes
on day 1, 2 and 3, followed by a 5-fluorouracil fixed dose of 350 mg/m2
administered by means of an i.v. infusion of 15 minutes on day 1, 2,
and 3. Vinorelbine was started at 25 mg/m2 diluted with 75-125 ml
of normal saline or dextrose 5%, and infused for 20 minutes on day 1
and 3. Dexametasone, 8 mg i.v. on day one and three and 4 mg i.v. on
day 2, was used as prophylactic antiemetic treatment. Treatment was
administered on an outpatient basis every three weeks.
A vinorelbine dose escalation (5 mg/m2 per level including three or
six patients each) was projected if no dose limiting toxicity occurred in
one out of three or two out of six patients per dose level, respectively.
Dose-limiting toxicities were defined as NCIC-CTG grade 3 granu-
locytopenia associated with grade >2 infection, and/or grade >2
constipation, mucositis, stomatitis or diarrhea.
Granulocytopenia without infection was not considered dose-limit-
ing toxicity; the prophylactic use of granulocyte colony stimulating
factors was not considered.
If a patient experienced any of dose-limiting toxic effect, the
vinorelbine dose was reduced by 20% for the rest of treatment period.
Pretreatment evaluation and follow-up studies
The pretreatment evaluation included medical history and physical
examination with tumor measurements: chest X-ray, complete blood
cell count, serum chemistries, liver function tests and tumour marker
determination; staging studies appropriate to define the extent of
metastatic disease which included abdominal ultrasound, thoracic
and/or abdominal CT, bone scan, as indicated by clinical or laboratory
examination.
Results
Patient characteristics
From May 1994 and June 1996, 45 patients with ad-
vanced breast cancer entered this phase I—II study: six
patients in the phase I study (three patients at dose level
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1 and three at dose level 2) and 39 in the subsequent
phase II study. All of the evaluable patients had at least
one measurable tumor site. Three patients were ineli-
gible: one refused the treatment after the first cycle
(phase I) and two had only unmeasurable bone disease
(phase II). The characteristics of the patients treated in
the phase II study are shown in Table 1 (n - 39). Their
median age was 51 years (range, 35 to 71); ECOG
performance status was 0-1 in 34 patients and 2 in five.
Twenty-five patients were postmenopausal, and 19 estro-
gen receptor positive. None of the patients had received
prior chemotherapy for advanced disease, although 21
of the 39 patients in the phase II study had received
prior chemotherapy in adjuvant setting, 13 of them
(33%) with an anthracycline-containing regimens. Thir-
teen patients had received prior adjuvant hormonother-
apy with tamoxifen. None of the patients had received
prior radiotherapy for advanced disease. The median
time elapsed from primary diagnosis to study entry was
13 months (range 0 to 113); none of the patients had
experienced failure of adjuvant anthracycline treatment
within six months of therapy completion (median time
since anthracyclines 17, range 8 to 76).
The site of metastatic disease were bone (36%), lymph-
nodes (41%), lung (41%), liver (38%) and soft tissue
(24%). The number of organ sites by patients were 1 in
18, 2 in 13 and more than 2 in 8 patients.
Toxicity
Phase I
Dose level 1. No dose-limiting toxicities were observed
in the first three patients treated at dose level 1 (19
cycles). Two patients developed grade 3 granulocyto-
penia at least once, and one grade 4, with nadir on day
9 and complete recovery within day 16, without fever.
Nonhematologic toxicity was minimal: grade 1 periph-
eral neuropathy in all three patients and grade 1 con-
stipation in one case.
Dose level 2. In this group of patients, vinorelbine was
administered at a dose of 30 mg/m2. Hematologic tox-
icity showed no differences in terms of the median nadir,
the days of nadir and the day of recovery; two patients
developed grade 4 granulocytopenia at least once, with
nadir on day 9 and complete recovery within day 16,
without fever. Grade 1 thrombocytopenia was observed
in one patient.
All patients treated at this dose level developed grade
4 peripheral neuropathy; grade 4 of 'ileus-like syndrome'
with fever (grade 2) requiring hospitalization and sup-
portive care was observed in two out of them.
Peripheral neuropathy occurred as an extrapyrami-
dal-like reaction with sharp posterior neck pain irradi-
ating to the nucal area, neck stiffness and difficulties in
chewing; the symptoms began within six days of starting
the cycle, lasted 48 to 72 hours and were followed by
constipation in all cases. The only medication that was
able to reverse this symptomatology was biperiden.
Table 1. Patient characteristics [phase II (n = 39)].
Age, years
Median
Range
ECOG performance status
0-1/2
Menopausal status
Pre/post
Estrogen receptor status
Negative
Positive
Unknown
Number of tumour site
1
2
> 2
Metastatic sites
Lung
Liver
Lymph-nodes
Skin
Breast
Bone
Prior adjuvant chemotherapy
with anthracycline
51
35-71
34/5
14/25
19
19
1
18
13
8
16
15
16
9
8
14
21
13
The higher incidence and extent of these symptoms
might be related to the short interval between the two
administration of vinorelbine which resulted in a high
peak blood concentration of vinorelbine.
After the enrollment of the first six patients, we
concluded that the maximum tolerated dose of vinorel-
bine is 25 mg/m2 when administered on a three-day
schedule, in combination with 5-fluorouracil and folinic
acid.
Phase II
All of the evaluable patients received at least one cycle
of therapy; the median number of cycles administered
was six (range: one to eight cycles).
Of the 229 cycles administered during the phase II
study, eight were delayed, six because of hematologic
toxicity, and the remaining two for non-medical reason.
Five patients required a dose reduction of vinorelbine in
13 cycles (by 25% in eight and by 50% in five cycles);
four cycles of 5-fluorouracil were administered at 75%
of total dose in one patient.
Mean dose per course of vinorelbine was 49 mg/m2
(range 25 to 50 mg/m2) and mean dose-intensity was
0.98 (17.7 mg/m2/wk) of the intended dose (18/mg/m2/
wk).
Mean dose per course of 5-fluorouracil was 1045
mg/m2, (range 787.5 to 1050 mg/m2) and mean dose-
intensity was 0.99 (377 mg/m2/wk) of the intented dose
of 379 mg/m2/wk.
The major dose-limiting toxicity was hematological,
with grade 4 granulocytopenia observed during at least
one cycle of treatment in 29 out of 39 patients (Table 2).
Recovery was fast and universal. Grade 3 and 4 nadirs
generally lasted no more than seven days. Sixteen epi-
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Table 2 Summary of hematologic toxicity (n = 39). Table 3 Summary of nonhematologic toxicities (NCIC-CTG criteria)
Toxicity
Granulocytopenia
Thrombocytopenia
Anemia
Hospitalization for granulocytopenic
complications
snrips nf fevpr associated with
NCIC-CTG
grade
1
2
3
A
4
1
2
3
4
1
2
3
4
ararmlnrvtm
No.
3
5
2
2
2
0
0
2
0
0
0
4
npnia
%
8%
13%
5%
4%
4%
-
-
4%
-
-
were
Toxicity
General
Esthenia
Injection-site reac-
tion
Abdominal pain
Fever
Alopecia
Digestive
Nausea/vomiting
Constipation
LJiarrnea
AnorexiaStomatitis
Peripheral neuropathy
Grade
1
No %
10 23%
5 12%
7 16%
13 30%
11 26%
23 54%
15 35%
A QO/
*t yyo
16 38%
13 30%
11 26%
2
No
5
1
3
3
4
7
6
—
5
2
3
%
12%
2%
7%
7%
9%
16%
14%
4%
12%
4%
7%
3
No
0
3
0
0
0
0
4
«
0
1
1
%
-
7%
-
-
-
-
9%
_
2%
2%
4
No %
0 -
0 -
0 -
0 -
0 -
0 -
0 -
n
u —
0 -
0 -
0 -
observed in eight patients during the 229 administered
cycles. Four patients were hospitalised for fever associ-
ated with grade 3 or 4 granulocytopenia and treated
with antibiotics containing beta-lactam and amino-
glycoside. None of the patients received granulocyte-
stimulating factors.
The non-hematological toxicities are listed in Table 3.
Mild peripheral neuropathy, limited to paresthesias and
insomnia, occurred in 15 patients, (grade 1 in 11 patients,
grade 2 in three and grade 3 in one). In no case neuro-
toxicity was dose-limiting and it was always reversible.
Of the 29 patients who received six cycles or more none
had residual peripheral neuropathy-related symptoms.
Constipation was reported in 25 patients (15 at grade
1, six at grade 2 and four at grade 3).
A low incidence of alopecia was observed, affecting
40% of patients with only 4 classified as grade 2. Other
side effects included nausea or vomiting, mucositis
and diarrhea, were generally mild. In three patients
with peripheral phlebitis requiring treatment, a central
venous access was implanted. No significant alterations
were observed in blood chemistry tests.
Response to therapy
Phase I
Dose level 1. One of the three patients treated at first
dose level achieved a complete response and two had
stable disease after two cycles of therapy.
Dose level 2. Two of the three patients treated at this
dose level achieved a partial response; one patient re-
fused the treatement after the first cycle and was not
evaluated for response.
In the first six patients we observed one complete
response, two partial responses and two cases of stable
disease.
This observation at this first dose level motivated the
phase II study.
Phase II
The response data are listed in Table 4. The median
duration of follow-up in the 39 evaluable patients was 15
months (range 4 to 31). The objective response rate (CR
plus PR) was 62% (95% CI, 47% to 77%), including
seven patients (18%) with CR and 17 (44%) with PR.
Nine patients experienced SD and six progressed on
treatment. The overall response rates by site were as-
sessed on measurable disease, and are displayed in Table
5. Responses were observed over the entire range of
metastatic sites, the overall response rate being 62% for
lung metastases, 60% for liver, 63% for lymph-nodes,
89% for skin, 88% for local relapses and 36% for bone
disease. The median response duration was 10 months
(range 6 to 24+). The median time to progression was
eight months (range 2 to 24+). The median survival time
has not been reached; the 12-month survival rate is 78%.
Discussion
For women with advanced breast cancer, chemotherapy
is, at best, a palliative measure, offering limited expecta-
tion of prolonged survival. The main goal of any treat-
ment chosen for metastatic disease is therefore to obtain
complete symptomatic relief, ideally through tumor
regression. The efficacy of available regimens yielding
response rates ranging from 40% to 90%, and median
response durations of 5-12 months, is well established,
while their positive effect on overall survival is contro-
versial.
Intensive treatments, such as doxorubicin, taxoids,
and platinum-containing regimens have shown signifi-
cant increase of response rates and duration, obtained
however at the cost of major toxic effects. Tiredness,
nausea, lack of appetite, and especially, alopecia are of
a significant subjective burden, and represent important
issues when discussing treatment options with patients.
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Table 4. Response to therapy (%).
Patients (n = 39)
Pretrcated with anthra-
cycline (n = 13)
PR
17(44)
6(46)
Table 5. Response by site (%).
PR
CR
7(18)
1(8)
CR
SD
9(23)
4(31)
SD
PD
6(15)
2(15)
PD
CR/
PR
24 (62)
7(54)
CR/
PR
Lung (n = 16)
Liver (n - 15)
Lymphnodes (n = 16)
Skin (n = 9)
Bone (n = 14)
Breast (n = 8)
7(43)
8(53)
7(44)
6(67)
4(29)
8(88)
3(19)
1(7)
3(19)
2(22)
1(7)
0
3(19)
4(27)
4(25)
1(11)
7(43)
1(12)
3(19)
2(13)
2(12)
0
3(21)
0
10(62)
9(60)
11(63)
8(89)
5(36)
8(88)
Although women with metastatic breast cancer are
offered more extensive therapeutic choices than patients
with most advanced malignancies, regimens with high
response rates and minimal toxicity are obviously war-
ranted.
Anthracycline-based therapy is considered the most
significant treatment for palliation due to its anti-tumor
effects and despite its subjective and objective toxicities.
However, the higher number of patients who receive
anthracycline-containing regimens in adjuvant or neo-
adjuvant programs, has increased the need for an effec-
tive and well tolerable regimen for the treatment of
patients relapsing after anthracycline exposure.
The response rates obtained with vinorelbine admin-
istered as single agent are similar to those of other drugs
(e.g., cyclophosphamide, methotrexate, doxorubicin,
mitoxantrone, 5-fluorouracil and mitomycin-Q, all con-
sidered effective as single agents in advanced breast
carcinoma, and typically used in chemotherapy regi-
mens for both advanced or operable disease [1].
Combination chemotherapy regimens are generally
thought to be more effective than single-agent chemo-
therapy in advanced breast cancer [28-31]. The high
remission rates observed with vinorelbine as a single
agent as well as its low toxicity profile, makes it a very
attractive proposition for combination with other active
compounds.
The combination of vinorelbine, 5-fluorouracil and
folinic acid, tested in this study was selected in an
attempt to obtain a regimen with a particularly favor-
able outline of subjective toxicity. The choice to admin-
ister vinorelbine on days 1 and 3 was made based upon
its plasma concentration profile which decrease in a tri-
exponential manner, with a terminal phase half-life of
about forty hours [32, 33]. Furthermore, most patients
do not tolerate a weekly dose of 30 mg/m2 (the recom-
mended dose for phase II studies), neutropenia being the
limiting toxicity, typically requiring dose reductions and
delays in administration. Vinorelbine can be easily com-
bined with 5-fluorouracil, a very active compound
against breast cancer [1, 22-24] which is only moder-
ately myelosuppressive.
In this study the combination of, 5-fluorouracil,
folinic acid and vinorelbine (FLN regimen), showed
considerable efficacy, with an overall response rate of
62% and a complete remission (CR) rate of 18% (95%
CI, 47% to 77%). The responses achieved were long-
lasting, with a median response duration of 10 months.
The median survival of the patient population has not
yet been reached; the 12-month survival is 78%.
It is interesting to note that the overall response rate
was not related to the patterns of metastatic presenta-
tion: responses were observed in 61% of visceral and
64% of non-visceral sites. Prior exposure to adjuvant
chemotherapy with anthracycline-containing regimens
(in the adjuvant setting) did not seem to influence
response: the remission rates were 58% in untreated
patients, and 54% in those who had been previously
treated; however, the number of these patients, is too
small and none of them experienced failure of adjuvant
anthracycline treatment within six months of therapy
completion (median 17, range 8 to 76).
The limiting toxicity of this combination, in which
vinorelbine was given on a three-day schedule, was
hematological: grade 3-4 neutropenia, recorded at
nadir, was experienced by almost all patients at least on
one occasion. Neutropenia, however, did not seem to be
cumulative and its duration was typically no longer than
seven days. Only eight courses required delayed admin-
istration, vinorelbine was administered at 98% of the
overall scheduled doses, and fluorouracil at 99%. The
neurological toxicity of vinorelbine was closely moni-
tored, but only one patient experienced grade 3 periph-
eral neuropathy with predominant numbness and para-
sthesiae. Autonomic neuropathy causing grade 4 consti-
pation was observed in only two patients who were
treated at the second dose level of vinorelbine (i.e., 30
mg/m2). The neurotoxicity was reversible in all cases.
No other significant toxic events were observed in other
organs, although four patients experienced grade 2
alopecia.
In conclusion, the FLN combination of vinorelbine,
5-fluorouracil and folinic acid proved to be an effective
first line treatment for metastatic breast cancer. Its
advantages over other commonly used cytotoxic combi-
nations is its excellent subjective tolerability. Patients
especially appreciate the very low incidence of nausea
and vomiting or alopecia. Moreover, 44% of the patients
complaining cancer-related symptoms at entry, showed
a reduction in their intensity during the course of the
first treatment.
The fact that this effective regimen was subjectively
well tolerated offers the opportunity for a number of
future developments, including further investigations on
the best way of combining these drugs, and its use as an
adjuvant and neoadjuvant treatment.
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